Planet 13 Holdings (PLNH) Income from Continuing Operations (2021 - 2026)
Planet 13 Holdings' (PLNH) quarterly Income from Continuing Operations came in at 8095802.0 in Q1 2026, down 180.63% year-on-year from 10041119.36 in Q1 2025, and down 215.53% on a QoQ basis from 7007274.0 in Q4 2025.
Planet 13 Holdings (PLNH) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has 6 years of Income from Continuing Operations data on file, last reported at 8095802.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 180.63% year-over-year to 8095802.0 in Q1 2026; TTM through Mar 2026 was 58345623.0, a 80.37% decrease from a year earlier, with the FY2025 full-year figure at 52296988.0, down 46.87% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 8095802.0, down from 7007274.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for PLNH reached as high as 7007274.0 in Q4 2025 and fell as low as 46254236.0 in Q3 2023.
- Historically, Income from Continuing Operations has averaged 13632198.18 across 5 years, with a median of 8073146.0 in 2024.
- Across the five-year window, Income from Continuing Operations sank 2136.41% in 2022 and surged 149.18% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 44012228.0 in 2022, then surged by 67.6% to 14258281.0 in 2023, then gained by 0.07% to 14248508.0 in 2024, then jumped by 149.18% to 7007274.0 in 2025, then plunged by 215.53% to 8095802.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 8095802.0 in Q1 2026, 7007274.0 in Q4 2025, and 43955853.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Planet 13 Holdings | 39.35 Mn | 23.09 Mn | 9.41 Mn | -8.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.10 Mn |
| Dec 31, 2025 | 7.01 Mn |
| Sep 30, 2025 | -43.96 Mn |
| Jun 30, 2025 | -13.30 Mn |
| Mar 31, 2025 | -2.88 Mn |
| Dec 31, 2024 | -14.25 Mn |
| Sep 30, 2024 | -7.14 Mn |
| Jun 30, 2024 | -8.07 Mn |
| Mar 31, 2024 | -5.89 Mn |
| Dec 31, 2023 | -14.26 Mn |
| Sep 30, 2023 | -46.25 Mn |
| Jun 30, 2023 | -4.66 Mn |
| Mar 31, 2023 | -8.48 Mn |
| Dec 31, 2022 | -44.01 Mn |
| Sep 30, 2022 | -6.34 Mn |
| Jun 30, 2022 | -7.09 Mn |
| Mar 31, 2022 | -4.07 Mn |
| Dec 31, 2021 | -12.46 Mn |
| Sep 30, 2021 | 4.05 Mn |
| Jun 30, 2021 | 347,962.00 |